{"analyses":[{"ciLowerLimit":"-12.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-0.82","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"3.017","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.026","paramType":"Mean Difference (Final Values)","paramValue":"-6.75","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-18.80","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-8.04","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.737","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Mean Difference (Final Values)","paramValue":"-13.42","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.154","value":"-11.98"},{"groupId":"OG001","spread":"2.171","value":"-18.73"},{"groupId":"OG002","spread":"1.732","value":"-25.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"146"},{"groupId":"OG001","value":"147"},{"groupId":"OG002","value":"227"}],"units":"Participants"}],"description":"Skindex-16 AA was adapted from Skindex-16 for use among adults with alopecia areata. It examines the degree to which the participant is bothered by alopecia (hair loss) and associated symptoms. It is composed of 16 items grouped under 3 domains: Symptoms (4 items), Emotions (7 items), and Functioning (5 items). The score of each item ranges from 0 (never bothered) to 6 (always bothered). Symptoms domain score is sum of 4 items, range 0 to 24; Emotions domain score is sum of 7 items, range 0 to 42; Functioning score is sum of 5 items, range 0 to 30. Higher scores indicate a greater impact on quality of life.\n\nLS means was calculated using the ANCOVA model with geographic region, duration of current episode at Baseline (\\<4 years vs. ≥ 4years), treatment group, and baseline value as fixed factors.","dispersionType":"Standard Error","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"All randomized participants with baseline and at least one postbaseline Skindex-16 AA emotions domain score who had evaluable data for this outcome measure. The method used to handle missing data was modified last observation carried forward (mLOCF) which used the most recent nonmissing postbaseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 36","title":"Change From Baseline in Skindex-16 AA Emotions Domain Score at Week 36","type":"SECONDARY","unitOfMeasure":"score on a scale"}